Acuta Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

Acuta Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.23M	Sell	532,481 -59,627	-10%	-$540K	3.64%	8
2026 Q1	$5.02M	Sell	592,108 -460,887	-44%	-$4.39M	3.54%	9
2025 Q4	$12.8M	Sell	1,052,995 -112,211	-10%	-$1.36M	8.68%	4
2025 Q3	$13.6M	Buy	1,165,206 +150,266	+15%	+$1.8M	14.08%	1
2025 Q2	$9.42M	Sell	1,014,940 -204,784	-17%	-$1.6M	13.15%	1
2025 Q1	$8.94M	Buy	1,219,724 +108,653	+10%	+$835K	10.37%	1
2024 Q4	$9.49M	Sell	1,111,071 -79,000	-7%	-$771K	9.55%	1
2024 Q3	$10.4M	Sell	1,190,071 -1,581,059	-57%	-$13M	8.39%	2
2024 Q2	$19M	Buy	2,771,130 +135,843	+5%	+$839K	15.96%	1
2024 Q1	$24M	Buy	2,635,287 +1,325,287	+101%	+$9.41M	15.58%	1
2023 Q4	$5.84M	Buy	+1,310,000	New	+$3.87M	3.29%	13
2022 Q3	–	Sell	-13,171	Closed	-$53K	–	53
2022 Q2	$53K	Buy	+13,171	New	+$49.8K	0.03%	42

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acuta Capital Partners's OCUL Position: Q2 2026 in Review

Acuta Capital Partners reduced its Ocular Therapeutix (OCUL) stake by 10% in Q2 2026, selling an estimated $540K and leaving 532,481 shares worth $5.23M. The position accounts for 3.64% of the portfolio, ranked #8.

Acuta Capital Partners first reported a position in OCUL in Q2 2022 and has held it in 12 quarters since. The position peaked at $24M in Q1 2024. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Acuta Capital Partners held 532,481 shares of Ocular Therapeutix worth $5.23M as of Q2 2026.
Acuta Capital Partners sold 59,627 Ocular Therapeutix shares in Q2 2026, an estimated $540K.
Ocular Therapeutix made up 3.64% of Acuta Capital Partners's portfolio in Q2 2026, its #8 holding.
Acuta Capital Partners first reported a position in Ocular Therapeutix in Q2 2022 and has held it in 12 quarters since.
Acuta Capital Partners's Ocular Therapeutix position peaked at $24M in Q1 2024.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.